Titragesia (fentanyl transdermal) / Miravo - LARVOL DELTA

Management of breakthrough pain in children with cancer (J Pain Res) - "The most common and effective strategy seems to be multimodal analgesia that includes an immediate-release opioid (eg, morphine, fentanyl, hydromorphone, or diamorphine) administered intravenously by a patient-controlled analgesia pump...Intranasal fentanyl (or hydromorphone) may be an alternative, but no pediatric data have been published yet for commercially available fentanyl transmucosal application systems (ie, sublingual tablets/spray, buccal lozenge/tablet/film, and nasal spray), and these products cannot yet be recommended for use with children with cancer and breakthrough pain."

Review • Pain

Safety and efficacy of transdermal fentanyl in opioid naive and pretreated patients (WCP 2012) - Presentation time: Tuesday, August 28; 9:45 am; P=NA, N=60; Both transdermal fentanyl & morphine sulfate tablets produced satisfactory pain relief with a better quality of analgesia & less incidence of side effects were in favor of transdermal fentanyl patches

Clinical data • Pain

Pain management in the elderly: transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee and hip (Biomed Res Int) - P=NA, N=NA; "TDF significantly increased pain control and improved functioning and quality of life. Metoclopramide appeared to be of limited value in preventing nausea and vomiting."

Clinical data • Pain

Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain (Clin J Pain) - P=NA, N=19; Pubmed ID: 23328324; "The dose-adjusted serum fentanyl concentrations for all patients were significantly decreased at 15 to 24 hours after conversion compared with baseline, although pain intensity and the number of rescue events remained stable during the conversion. The dose-adjusted serum fentanyl concentrations at 9 to 24 hours were significantly reduced in the low albumin group compared with the normal albumin group (P<0.05)."

Clinical data • Pain

A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch (Biol Pharm Bull) - P=NA, N=92; "Pain intensities were significantly higher among patients in the low-nutrition group than among patients in the normal-nutrition group. NRS 2002 scores showed a significant positive correlation with the pain intensities. In 52 of 92 patients, who were evaluated using the NRS 2002 score and pain intensity on day 30 after FP [transdermal fentanyl patch] application, the changes in NRS 2002 scores were significantly related to changes in pain intensities (odds ratio, 30.0; 95% confidence interval, 4.48-200.97; p=0.0005)."

Retrospective data • Pain

Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial (Yonsei Med J) - P=NA, N=200; "Overall, pain relief was obtained by all three groups [loxoprofen, tramadol/acetaminophen, and transdermal fentanyl groups]. Most patients did not show progressive OA [osteoarthritis] changes; however, 3 patients in the transdermal fentanyl group showed progressive OA changes during the 12 weeks of treatment. These 3 patients used significantly higher doses than others in the transdermal fentanyl group."

Clinical data • Pain

Efficacy of Transdermal Fentanyl Patches in Relief of Acute Postoperative Pain After Mastectomy (clinicaltrials.gov) - P4; N=60; Recruiting; Sponsor: South Egypt Cancer Institute

New P4 trial • Biosimilar • Breast Cancer • Demo Pain • Oncology • Pain

Comparative assessment of 3 techniques of preemptive pain management in spine surgery patients: epidural analgesia, transdermal fentanyl therapeutic system durogesic matrix, NSAIDs (WCP 2012) - Presentation time: Wednesday, August 29; 3:15 pm: P=NA, N=67; In epidural analgesia group an adequate level of postoperative analgesia was achieved in 76%, moderate pain in 24% (4-6 points on VAS); In TTS group adequate level of analgesia found in 47%, moderate pain was in 53%; In the NSAID group only in 35% patients was obtained adequate pain relief, 47% were were in moderate pain and 18% - severe pain (> 6.0 points on VAS)

Clinical data • Pain

Fentanyl Patch Pharmacokinetics in Healthy Adults (clinicaltrials.gov) - P4; N=24; Recruiting; Sponsor: University of Maryland; Not yet recruiting ➔ Recruiting; Initiation date: Sep 2015 ➔ Jan 2015

Enrollment open • Trial initiation date • Biosimilar